DBV Technologies (NASDAQ:DBVT) Issues Earnings Results

DBV Technologies (NASDAQ:DBVT) released its quarterly earnings results on Thursday. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.48), FiscalAI reports. The firm had revenue of $0.70 million for the quarter, compared to the consensus estimate of $0.78 million. DBV Technologies had a negative net margin of 2,895.37% and a negative return on equity of 129.88%.

Here are the key takeaways from DBV Technologies’ conference call:

• DBV said it remains on track to submit an optimized BLA for Viaskin Peanut in the third quarter of 2026, and emphasized that the FDA has not requested additional data. Management said the remaining work is focused on formatting, mapping, and organizing existing CMC and biostatistics information.
• The company said it is building out commercial infrastructure in anticipation of a possible approval, including market access, patient services, brand readiness, field force planning, and launch operations. Management also said it is preparing manufacturing and supply-chain capacity for potential peak demand.
• DBV announced that recruitment has closed for the COMFORT Toddlers safety study in children ages one to three, and it still expects to file by year-end. The study is a six-month supplemental safety trial with no efficacy component.
• New clinical and epidemiological data were presented supporting Viaskin Peanut, including additional VITESSE subgroup analyses showing consistent treatment effects and a new prevalence study indicating U.S. pediatric peanut allergy remains around 2%. Management said this reinforces the size and persistence of the addressable market.
• The company said it is funded into the third quarter of 2027, giving it runway to support operations and commercial preparedness. Management described THRIVE as an early-stage, first-of-its-kind phase II study in infants, but said it is not currently intended as a registration trial.

DBV Technologies Price Performance

DBVT opened at $14.86 on Friday. The company has a 50 day simple moving average of $17.24 and a two-hundred day simple moving average of $19.51. The firm has a market cap of $879.86 million, a P/E ratio of -3.33 and a beta of -0.95. DBV Technologies has a 1-year low of $8.51 and a 1-year high of $26.18.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Citizens Jmp upped their price objective on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a research report on Tuesday, June 30th. Guggenheim reaffirmed a “buy” rating and set a $51.00 price target on shares of DBV Technologies in a research report on Monday, May 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of DBV Technologies in a report on Monday, June 29th. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a report on Friday, May 1st. Finally, Wall Street Zen cut shares of DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, DBV Technologies currently has an average rating of “Moderate Buy” and a consensus price target of $48.50.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Ikarian Capital LLC bought a new stake in DBV Technologies during the 4th quarter valued at approximately $10,064,000. Vestal Point Capital LP purchased a new stake in DBV Technologies in the 4th quarter worth $5,751,000. Squadron Capital Management LLC bought a new position in shares of DBV Technologies during the 4th quarter valued at about $4,601,000. Millennium Management LLC grew its position in shares of DBV Technologies by 89.7% during the fourth quarter. Millennium Management LLC now owns 640,885 shares of the company’s stock valued at $12,286,000 after purchasing an additional 303,022 shares in the last quarter. Finally, Engineers Gate Manager LP purchased a new position in shares of DBV Technologies during the fourth quarter valued at about $479,000. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.